Multiple sclerosis

  • MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance
    Martijn T Wijburg, Birgit I Witte, Anke Vennegoor, Stefan D Roosendaal, Esther Sanchez, Yaou Liu, Carine O Martins Jarnalo, Bernard MJ Uitdehaag, Frederik Barkhof, Joep Killestein, Mike P Wattjes
  • Back on the scent: the olfactory system in CNS demyelinating diseases
    Albert Joseph, Gabriele C DeLuca
  • Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
    Patrick Waters, Markus Reindl, Albert Saiz, Kathrin Schanda, Friederike Tuller, Vlastimil Kral, Petra Nytrova, Ondrej Sobek, Helle Hvilsted Nielsen, Torben Barington, Søren T Lillevang, Zsolt Illes, Kristin Rentzsch, Achim Berthele, Tímea Berki, Letizia Granieri, Antonio Bertolotto, Bruno Giometto, Luigi Zuliani, Dörte Hamann, E Daniëlle van Pelt, Rogier Hintzen, Romana Höftberger, Carme Costa, Manuel Comabella, Xavier Montalban, Mar Tintoré, Aksel Siva, Ayse Altintas, Günnur Deniz, Mark Woodhall, Jacqueline Palace, Friedemann Paul, Hans-Peter Hartung, Orhan Aktas, Sven Jarius, Brigitte Wildemann, Christian Vedeler, Anne Ruiz, M Isabel Leite, Peter Trillenberg, Monika Probst, Sandra Saschenbrecker, Angela Vincent, Romain Marignier
  • Is Google good enough for medicine?
    Cindy Shin-Yi Lin, William Huynh
  • Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation
    Bianca Weinstock-Guttman, Jesper Hagemeier, Katelyn S Kavak, Vasu Saini, Kara Patrick, Deepa P Ramasamy, Muhammad Nadeem, Ellen Carl, David Hojnacki, Robert Zivadinov
  • Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
    F Patti, S Messina, C Solaro, M P Amato, R Bergamaschi, S Bonavita, R Bruno Bossio, V Brescia Morra, G F Costantino, P Cavalla, D Centonze, G Comi, S Cottone, M Danni, A Francia, A Gajofatto, C Gasperini, A Ghezzi, A Iudice, G Lus, G T Maniscalco, M G Marrosu, M Matta, M Mirabella, E Montanari, C Pozzilli, M Rovaris, E Sessa, D Spitaleri, M Trojano, P Valentino, M Zappia
  • MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS
    Mike P Wattjes, Martijn T Wijburg, Anke Vennegoor, Birgit I Witte, Marlieke de Vos, Nancy D Richert, Bernard M J Uitdehaag, Frederik Barkhof, Joep Killestein
  • Extended interval dosing of natalizumab in multiple sclerosis
    L Zhovtis Ryerson, T C Frohman, J Foley, I Kister, B Weinstock-Guttman, C Tornatore, K Pandey, S Donnelly, S Pawate, R Bomprezzi, D Smith, C Kolb, S Qureshi, D Okuda, J Kalina, Z Rimler, R Green, N Monson, T Hoyt, M Bradshaw, J Fallon, E Chamot, M Bucello, S Beh, G Cutter, E Major, J Herbert, E M Frohman
  • Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease
    Christian Lechner, Matthias Baumann, Eva-Maria Hennes, Kathrin Schanda, Klaus Marquard, Michael Karenfort, Steffen Leiz, Daniela Pohl, Sunita Venkateswaran, Martin Pritsch, Johannes Koch, Mareike Schimmel, Martin Häusler, Andrea Klein, Astrid Blaschek, Charlotte Thiels, Thomas Lücke, Ursula Gruber-Sedlmayr, Barbara Kornek, Andreas Hahn, Frank Leypoldt, Torsten Sandrieser, Helge Gallwitz, Johannes Stoffels, Christoph Korenke, Markus Reindl, Kevin Rostásy
  • A longitudinal study of cortical grey matter lesion subtypes in relapse-onset multiple sclerosis
    Varun Sethi, Tarek Yousry, Nils Muhlert, Daniel J Tozer, Daniel Altmann, Maria Ron, Claudia Wheeler-Kingshott, David H Miller, Declan T Chard

Pages